Functional Neurosurgery
Functional Neurosurgery
Bottom Line
DBS targets by indication: STN or GPi for PD (STN allows medication reduction; GPi safer cognitive profile), VIM for essential tremor, GPi for dystonia, ANT for epilepsy. DBS candidacy for PD: motor fluctuations/dyskinesias despite optimized meds, levodopa-responsive symptoms, no significant dementia. Epilepsy neuromodulation: VNS (open-loop, left vagus), RNS (closed-loop, eloquent cortex/bilateral foci), ANT-DBS (SANTE trial). Baclofen withdrawal: life-threatening emergency — hyperthermia, rhabdomyolysis, seizures, multi-organ failure; mimics NMS. MVD: first-line surgery for trigeminal neuralgia; SCA is the most common offending vessel; ~80% pain-free. SCS: gate control theory; superior to reoperation for FBSS.
HighYield Pearls
- Best DBS predictor: robust & sustained levodopa response — if patient doesn’t respond to L-dopa, they will NOT respond to STN/GPi-DBS.
- Atypical parkinsonism = NO DBS: MSA, PSP, CBD, DLB — no benefit and can worsen axial/autonomic/cognitive symptoms.
- STN vs GPi for PD: STN → allows levodopa reduction but ↑ mood/cognition/speech risk; GPi → direct antidyskinetic effect, safer in cognitively vulnerable / psychiatric patients.
- VIM target: essential tremor & tremor-dominant PD — dramatic tremor suppression; also the MRgFUS thalamotomy target.
- GPi-DBS for dystonia: DYT1 generalized dystonia is the best responder; benefit emerges over weeks–months (not minutes like PD); also used for tardive dystonia and status dystonicus.
- ANT-DBS for epilepsy: SANTE trial → FDA-approved 2018 for refractory focal epilepsy; bilateral anterior thalamic nucleus.
- MRgFUS (Exablate Neuro): non-invasive, incisionless — but lesion is PERMANENT and IRREVERSIBLE; FDA-labeled indications include unilateral VIM thalamotomy for ET (2016), VIM thalamotomy for tremor-dominant PD (2018), unilateral GPi pallidotomy for advanced PD motor complications (2021; NOT STN), staged bilateral VIM thalamotomy for ET (2022), and staged bilateral pallidothalamic tractotomy (PTT) for selected advanced PD (July 2025).
- Intrathecal baclofen withdrawal: pump failure → high fever + autonomic instability + seizures + rhabdomyolysis (mimics NMS) — HIGH MORTALITY; treat with oral baclofen + supportive care; do NOT use dantrolene as primary therapy.
- DBS contraindications for PD: dementia, severe axial symptoms (gait freezing, postural instability that don’t respond to L-dopa), active psychiatric instability, atypical parkinsonism.
- DBS hemorrhage risk: 1–2% at electrode placement — hold antiplatelets/anticoagulants perioperatively & tight BP control during stereotactic insertion.
🔍 Quick ReferenceTarget / indication · Outcomes · Complications / monitoring
Target / indication
- STN (subthalamic nucleus) → PD with motor fluctuations + dyskinesias + tremor (most common DBS target)
- GPi (internal globus pallidus) → PD with cognitive/psychiatric concerns or severe dyskinesias; primary target for dystonia (esp. DYT1)
- VIM (ventral intermediate thalamic nucleus) → essential tremor & tremor-dominant PD (DBS or MRgFUS thalamotomy)
- ANT (anterior thalamic nucleus) → refractory focal epilepsy (SANTE trial, FDA 2018)
- Fornix-DBS → Alzheimer disease (investigational)
- Anterior limb internal capsule / NAc / STN → refractory OCD (investigational/HDE)
- Subgenual cingulate (Cg25) / centromedian thalamus / GPi → refractory depression / Tourette syndrome (investigational)
- Dorsal column SCS / DRG stimulation → failed back surgery syndrome, CRPS, focal neuropathic pain
Outcomes / pearls
- Robust levodopa response → best predictor of DBS benefit in PD
- 30–50% levodopa equivalent dose reduction → STN-DBS (GPi does NOT meaningfully reduce meds)
- Direct antidyskinetic effect → GPi-DBS
- Effect over weeks–months (not minutes) → GPi-DBS for dystonia
- Incisionless, no implant, permanent lesion → MRgFUS / Exablate thalamotomy or pallidotomy
- MER (microelectrode recording) single-unit firing → intraoperative target verification
- Capsulotomy / cingulotomy → ablative option for refractory OCD / depression
- Intrathecal baclofen pump → severe spasticity from MS, SCI, CP, ALS refractory to oral therapy
Complications / monitoring
- Intracranial hemorrhage 1–2% → DBS electrode placement (hold antiplatelets, control BP)
- Hardware infection 1–5% → DBS / IPG / SCS system
- Mood/cognitive/speech worsening, impulsivity → STN-DBS (capsule spread)
- High fever + autonomic storm + seizures + rhabdomyolysis → intrathecal baclofen pump failure / withdrawal (mimics NMS, high mortality)
- Permanent & irreversible lesion → MRgFUS / radiofrequency thalamotomy or pallidotomy (vs reversible DBS)
- MRI restrictions (1.5T head coil, conditional) → DBS hardware (check device generation/manual)
- Battery depletion q3–5 yr (non-rechargeable) → IPG replacement
- Reservoir refills q1–3 mo → intrathecal baclofen / opiate pump maintenance
Deep Brain Stimulation (DBS) — Overview
Mechanism and Principles
- Mechanism: high-frequency electrical stimulation of target nuclei → modulates pathological circuit activity (inhibits/disrupts abnormal oscillatory patterns)
- Does NOT simply “lesion” the target — involves complex effects on local neurons, afferent/efferent fibers, and network-level modulation
- Reversible and adjustable — key advantage over ablative procedures (thalamotomy, pallidotomy)
- Bilateral stimulation is possible (unlike ablative lesioning where bilateral lesions carry high morbidity)
Components
- Electrode (lead): implanted stereotactically into brain target; 4–8 contacts for current delivery
- Extension wire: tunneled subcutaneously from scalp to chest
- IPG (implantable pulse generator): battery/stimulator implanted in infraclavicular subcutaneous pocket; non-rechargeable (3–5 year battery) or rechargeable (~15 years)
Surgical Placement Techniques
| Technique | Details |
|---|---|
| Microelectrode recording (MER) | Awake surgery; records single-unit neuronal activity to confirm target; gold standard for physiological localization; longer operative time |
| MRI-guided (interventional MRI) | Asleep surgery; real-time MRI verification of lead placement; no neurophysiology needed; shorter procedure; increasingly used |
| Frame-based stereotaxy | Leksell or CRW frame; highest mechanical accuracy (<1 mm); standard approach |
| Frameless stereotaxy | Robot-assisted or navigation-guided; comparable accuracy; improved patient comfort |
DBS Programming Parameters
- Frequency: typically 130–185 Hz (high frequency); lower frequencies (≤60 Hz) may worsen symptoms or be used for specific indications (e.g., gait freezing)
- Amplitude (voltage/current): determines spread of stimulation field; higher amplitude = wider field but more side effects
- Pulse width: typically 60–90 μs; wider pulse width recruits more axons; narrower = more selective
- Monopolar vs. bipolar: monopolar = wider field (IPG is positive pole); bipolar = more focused stimulation between two contacts
- Directional leads: segmented contacts allow steering current toward target and away from side-effect-causing structures
Board Pearls
- DBS is reversible and adjustable — the primary advantage over ablative surgery (thalamotomy, pallidotomy, MRgFUS)
- Three components: electrode + extension wire + IPG — any component can malfunction causing loss of benefit
- High-frequency stimulation (130–185 Hz) is standard; low frequency may paradoxically worsen symptoms
- MRI compatibility depends on the DBS system — older devices have significant MRI restrictions; newer systems are conditionally MRI-compatible
DBS for Parkinson Disease
DBS Targets: STN vs. GPi
| Feature | STN-DBS | GPi-DBS |
|---|---|---|
| Most common? | Yes — most widely used target for PD | Increasingly used; preferred in select cases |
| Medication reduction | Allows 30–50% levodopa equivalent dose reduction | Does NOT allow significant medication reduction |
| Dyskinesia control | Indirect — via medication reduction | Direct antidyskinetic effect — better for severe dyskinesias |
| Tremor | Slightly better tremor suppression | Effective but may be slightly less |
| Cognitive/mood effects | Higher risk of depression, impulsivity, apathy | Safer cognitive and behavioral profile |
| Target size | Smaller → narrower therapeutic window; more precise programming needed | Larger → more forgiving programming |
| Battery life | Lower stimulation parameters → longer battery life | Higher parameters → shorter battery life |
| Best candidate | Younger, cognitively intact, wants medication reduction | Cognitive concerns, psychiatric comorbidity, severe dyskinesias |
Patient Selection Criteria — CAPSIT-PD
CAPSIT-PD (Core Assessment Program for Surgical Interventional Therapies in Parkinson Disease) is the standard selection framework:
- Robust levodopa response: ≥30% improvement in UPDRS-III on levodopa challenge — DBS improves what levodopa improves
- Motor fluctuations and/or dyskinesias despite optimized dopaminergic therapy
- No dementia — cognitive impairment worsens post-DBS (especially STN); screen with formal neuropsych testing
- No severe psychiatric comorbidity — active depression, psychosis, or severe impulse-control disorders are contraindications
- MRI without significant structural lesions (excludes vascular parkinsonism, NPH, atypical parkinsonism)
- Disease duration typically ≥4 years to ensure correct diagnosis (excludes atypical parkinsonism)
- Adequate general health and realistic expectations about outcomes
Symptoms — What Responds vs. What Does Not
| Responds Well to DBS | Does NOT Respond to DBS |
|---|---|
| Tremor (best response) | Gait freezing (axial symptom) |
| Rigidity | Speech/hypophonia |
| Bradykinesia | Postural instability |
| Motor fluctuations (on-off) | Dementia/cognitive symptoms |
| Levodopa-induced dyskinesias | Dysphagia |
Rule: levodopa-unresponsive symptoms are DBS-unresponsive symptoms — these are axial/midline features that reflect non-dopaminergic degeneration.
Key Trials
- EARLYSTIM (Schuepbach et al., NEJM 2013): STN-DBS in early motor complications (mean 7.5 years disease duration) → superior quality of life vs. best medical therapy; supports earlier DBS intervention in select patients
- PD SURG (Williams et al., Lancet Neurol 2010): DBS + best medical therapy superior to best medical therapy alone at 1 year; benefits sustained at 3 years
- VA Cooperative Study (Follett et al., NEJM 2010): STN and GPi showed similar motor improvement at 24 months; GPi had a more favorable neurocognitive/mood profile, while STN was associated with worsening processing speed and a trend toward worsening depression
Clinical Pearl
The best predictor of DBS outcome in PD is the levodopa response. A patient’s best “on” state on medication approximates their best state with DBS. If a symptom does not improve with levodopa (e.g., freezing of gait, postural instability, speech), it will not improve with DBS.
Board Pearls
- STN-DBS allows 30–50% medication reduction; GPi-DBS does not — single most-tested distinction on boards
- GPi-DBS preferred when cognitive concerns exist — safer behavioral/cognitive profile than STN
- DBS improves what levodopa improves — levodopa-unresponsive symptoms (falls, freezing, speech, dementia) do NOT improve with DBS
- Tremor has the best response to DBS of all PD motor features
- EARLYSTIM supports DBS earlier in the disease course (at onset of motor complications, not just late stage)
- ≥30% UPDRS-III improvement on levodopa challenge is the standard candidacy threshold
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.